Business, energy, technology, markets and global industry news from Business News Today

VERAFEYE

PharmaDeviceNews VERAFEYE
LUMA Vision’s VERAFEYE platform integrates intracardiac ultrasound, live 3D cardiac anatomy and catheter tracking as the company prepares for a United States commercial launch. Representative image.
Features & Analysis

Electrophysiologists already have mapping and ultrasound. Why does LUMA Vision think they need VERAFEYE?

LUMA Vision has secured another FDA clearance expanding VERAFEYE ahead of a planned early-2027 United States launch. The system combines intracardiac ultrasound, live 3D anatomical reconstruction, catheter tracking and ablation guidance, challenging the electrophysiology lab’s traditional reliance on several separate imaging and navigation tools.

Read More
Medical Devices & Diagnostics

Can VERAFEYE replace multiple tools in the electrophysiology lab? LUMA Vision moves closer to launch

LUMA Vision expands FDA clearance for VERAFEYE, integrating cardiac imaging, 3D anatomy and catheter tracking ahead of its planned 2027 launch.

Read More
Medical Devices & Diagnostics

FDA clears expanded LUMA Vision VERAFEYE platform for real-time cardiac mapping and catheter guidance

LUMA Vision has secured additional FDA clearance for VERAFEYE, integrating real-time 2D and 3D cardiac anatomy, catheter tracking and procedural guidance ahead of a planned 2027 U.S. launch.

Read More